Amgen to release results of Repatha cardiovascular outcomes trial

Amgen's results of its Repatha (evolocumab) cardiovascular outcomes trial will be released at the American College of Cardiology's 66th Annual Scientific Session, which is set to take place in Washington, D.C. March 17-19.
"As cardiovascular disease remains the leading health burden in the world, we sought to answer whether adding Repatha would provide further risk reduction for patients who are already well-treated with statins," Dr. Sean E. Harper, Amgen's executive vice president of research and development, said in a statement. "The data from this large cardiovascular outcomes trial will provide a new understanding of the role that Repatha plays in the lives of the millions of people living with uncontrolled high cholesterol."
In addition to presenting data from the Repatha trial, the company will unveil new data across its cardiovascular portfolio. It noted the presentation will include two analyses that explore prescription rejection rates and access barriers for PCSK9 inhibitors.
"As we prepare to share our outcomes data with the cardiovascular community, patients continue to face unacceptable barriers to getting the additional LDL lowering that Repatha can provide, despite their physician's treatment recommendations,” Harper said.